Peptides and combination of peptides for use in immunotherapy against various tumors
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A fusion protein comprising a peptide consisting of the amino acid sequence of ALAGIVTNV (SEQ ID NO: 246) and N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).
2. A pharmaceutical composition comprising
a peptide consisting of the amino acid sequence of ALAGIVTNV (SEQ ID NO: 246) and an adjuvant; or
a fusion protein comprising a peptide consisting of the amino acid sequence of ALAGIVTNV (SEQ ID NO: 246) and the N-terminal amino acids 1 to 80 of the HLA-DR antigen-associated invariant chain (Ii);
wherein said composition comprises a pharmaceutically acceptable carrier, and optionally, pharmaceutically acceptable excipients and/or stabilizers.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of saline, Ringer's solution, and dextrose solution.
4. The pharmaceutical composition of claim 2 , wherein said composition comprises a peptide consisting of the amino acid sequence of ALAGIVTNV (SEQ ID NO: 246, an adjuvant, a pharmaceutically acceptable carrier, and a pharmaceutically acceptable excipient and/or stabilizer.
5. The pharmaceutical composition of claim 4 , wherein the pharmaceutically acceptable excipients are selected from the group consisting of buffers, binding agents, diluents, flavors, and lubricants.
6. The pharmaceutical composition of claim 2 , wherein said composition consists essentially of a peptide consisting of the amino acid sequence of ALAGIVTNV (SEQ ID NO: 246, an adjuvant, and a pharmaceutically acceptable carrier.
7. An artificial antigen presenting cell (aAPC) comprising an WIC complex of a peptide consisting of the amino acid sequence of ALAGIVTNV (SEQ ID NO: 246) on the surface of the aAPC.
8. The aAPC of claim 7 , further comprising an anti-CD28 antibody on the surface of the aAPC.
9. The pharmaceutical composition of claim 2 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, particulate formulations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.